DNMT3A mutations occur in about 20% of patients with AML and about 17% of patients with T-cell acute lymphoblastic leukaemia (T-ALL), and are associated with poor disease outcome [35,36,37,38]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.